Table 2.
Vaccines under clinical evaluation for COVID-19 according to the WHO as of October 29, 2020. The information provided here are based on the analysis from official website of WHO [226].
| Platform | Candidate vaccine (Developer) |
Current stage (participants) |
Status (completion date) |
Subject | Study location |
|---|---|---|---|---|---|
| Inactivated | Inactivated + alum (Sinovac) |
Phase 3 NCT04456595 (8,870) Phase 1/2 NCT04383574 (422) NCT04352608 (744) |
Recruiting (October 2021) Recruiting (December 2020) |
18−59 years 18−59 years |
Brazil China |
| Inactivated (Wuhan Institute of Biological Products/Sinopharm) |
Phase 3 ChiCTR2000034780 (15,000) Phase 1/2 ChiCTR2000031809 809 (1,120) |
Recruiting (July 2021) Completed |
≥18 years 18−59 years |
United Arab Emirates China |
|
| Inactivated (Beijing Institute of Biological Products/Sinopharm) |
Phase 3 ChiCTR2000034780 (15,000) Phase 1/2 ChiCTR2000032 459 (1,904) |
Recruiting (July 2021) Recruiting (-) |
≥ 18 years ≥ 3 years |
China China |
|
| Inactivated (Research Institute for Biological Safety Problems, Rep of Kazakhstan | Phase 1/2 NCT04530357 (244) |
Recruiting (April 2021) |
18−100 years |
Kazakhstan | |
| Inactivated (Beijing M Inhai Biotechnology Co., Ltd.,) |
Phase 1 ChiCTR2000038804 (180) |
Not yet recruiting (-) |
≥ 18 years | China | |
| Inactivated (Institute of Medical Biology Chinese Academy of Medical Sciences) |
Phase 1/2 NCT04412538 (942) NCT04470609 (471) |
Recruiting (September 2021) (November 2021) |
18−59 years ≥ 60 years |
China China |
|
| Whole-Virion inactivated (Bharat Biotech) | Phase 1/2 NCT04471519 (755) |
Active, not recruit ing (June 2021) |
12−65 years |
India | |
| Non-replicating viral |
ChAdOx1-S (University of Oxford/ Astrazeneca) |
Phase 3 ISRCTN8995424 (2000) Phase 2b/3 2020-001228-32 (-) Phase 1/2 PACTR20200692216 5132 (2000) NCT04324606 (1090) |
Recruiting (July 2021) Recruiting (-) Recruiting (December 2021) Completed |
18−55 years ≥ 18 years 18−65 years with or wit hout HIV 18−55 years |
Brazil UK South Africa UK |
| Adenovirus Type 5 Vector (Cansino Biological Inc./Beijing Institute of Biotechnology) |
Phase 3 NCT04526990 (40,000) |
Recruiting (January 2022) |
≥ 18 years | Pakistan | |
| Phase 2 ChiCTR2000031781 (500) Phase 1 ChiCTR2000030906 (108) |
Completed Completed |
≥ 18 years 18−60 years |
China China |
||
| Replication defective Simian Adenovirus (GRAd) encoding S (ReiThera/LEUKOCA RE/Univercells) |
Phase 1 NCT04528641 (90) |
Recruiting (July 2021) |
18−85 years |
Italy | |
| Ad5-nCoV(Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China |
Phase 1 NCT04552366 (144) |
Recruiting (June 2021) |
≥ 18 years | China | |
| Adeno-based (Gamaleya Research institute) |
Phase 3 NCT04530396 (40,000) |
Recruiting (May 2021) |
≥ 18 years | Russia | |
| Phase 1/2 NCT04436471 NCT04437875 (38) |
Active, not recruit ing (August 2020) |
18−60 years |
Russia | ||
| Ad26COVS1(Janssen Pharmaceutical Companies) |
Phase 3 NCT04505722 (60,000) |
Recruiting (March 2023) |
≥ 18 years | USA, Peru Argentina Brazil, Chile Mexico, South Africa, Columbia |
|
| Phase 1/2 NCT04436276 (1045) |
Recruiting (November 2023) |
≥ 18 years | USA Belgium |
||
| Ad5 adjuvanted Oral Vaccine platform (Vaxart ) |
Phase 1 NCT04563702 (48) |
Recruiting (October 2021) |
18−54 years |
USA | |
| MVA-SARS-2-S (Ludwing-Maximillians- -University of Munich) |
Phase1 NCT04569383 (30) |
Not yet recruiting (May 2021) | 18−55 years |
Germany | |
| RNA | LNP-encapsulated mR NA (Moderna/ NIAID) |
Phase 3 NCT04470427 (30,000) Phase 2 NCT04405076 (600) Phase 1 NCT04283461 (155) |
Recruiting (October 2022) Active, not recruit ing (August 2021) Completed |
≥ 18 years ≥ 18 years 18−99 years |
USA USA USA |
| 3LNP-mRNAs (BioNTech/Fosun Pharma/Pfizer) |
Phase 2/3 NCT04368728 (43,998) Phase 1/2 2020-001038-36 (444) Phase 1 ChiCTR2000034825 (144) |
Recruiting (November 2022) Recruiting (-) Recruiting (December 2020) |
18−85 Years ≥ 18 years ≥ 18 years |
USA Argentina Brazil Germany China |
|
| LNP-nCoVsaRNA (Imperial College London ) |
Phase 1 ISRCTN17072692 (320) |
Recruiting (July 2021) |
18−75 years |
UK | |
| mRNA (Curevac) | Phase 2 NCT04515 147 (691) |
Not yet recruiting (November 2021) |
≥ 18 years | Germany Belgium |
|
| Phase 1 NCT04449276 (168) |
Recruiting (August 2021) |
18−60 years |
Germany Belgium |
||
| mRNA (People’s Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech) |
Phase 1 ChiCTR2000034112 (168) |
Not yet recruiting (December 2021) |
18−80 years |
China | |
| mRNA(Arcturus/Duke -Nus) |
Phase 1/2 NCT04480957 (92) |
Recruiting (January 2021) |
21−80 years |
Singapore | |
| DNA | DNA plasmid vaccine with electroporation (Inovio Pharmaceuticals/International Vaccine Institute) |
Phase 1/2 NCT04447781(160) Phase 1 NCT04336410 (120) |
Recruiting (February 2022) Recruting (July 2021) |
19−64 Years ≥ 18 years |
Republic of Korea USA |
| DNA plasmid + Adjuvant (Osaka University/AnGes/TakaraBio) | Phase 1/2 NCT04463472 (30) |
Recruiting (July 2021) |
20−55 years |
Japan | |
| DNA plasmid vaccine (Cadila Healthcare Limited) |
Phase 1/2 CTRI/2020/07/0 263552 (1048) |
Recruiting (July 2021) |
18−55 years |
India | |
| DNAVaccine (GX-19) (Genexine Consortium ) |
Phase 1 NCT04445389 (210) |
Recruiting (June 2022) |
18−50 years |
Republic of Korea |
|
| Protein Subunit |
Full length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M (Novavax) |
Phase 3 (2020-004123-16) (-) Phase 2b NCT04533399 (2,900) Phase 1/2 NCT04368988 (131) |
Recruiting (-) Recruiting (November 2021) Recruiting (July 2021) |
≥ 18 years 18−64 Years 18−59 years |
UK South Africa USA |
| Native-like Trimeric subunit spike protein vaccine (Clover Bioph Pharmaceuticals Inc. /GSK/Dynavax) |
Phase 1 NCT0440590 (150) |
Recruiting (March 2021) |
18−75 years |
Australia | |
| RBD (Baculovirus production expressed in Sf9 cells) (West China Hospital, Sichuan University |
Phase 1 ChiCTR2000037518 (168) |
Recruiting (August 2021) |
≥ 18 years | China | |
| Adjuvanted recombinat protein (RBD Di mer) (Anhui Zhifei Longcom Biopharmaceutical /Institute of Microbiology , Chinese Academy of Sciences) |
Phase 2 NCT04466085 (900) Phase 1 NCT04445194 (50) |
Recruiting (December 2021) Recruiting (September 2021) |
18−59 Years 18−59 years |
China China |
|
| S protein (Baculovirus Production) Sanofi Pasteur/GSK |
Phase 1/2 NCT04537208 (440) |
Recruiting (October 2021) |
≥ 18 years | USA | |
| Recombinant spike protein with AdvaxTM Adjuvant (Vaxine Pty Ltd./Medytox) |
Phase 1 NCT04453852 (40) |
Recruiting (July 2021) |
18−65 years |
Australia | |
| SARS-CoV-2 HLA- DR peptides (University Hospital Tuebingen) |
Phase 1 NCT04546841 (36) |
Not yet recruiting (December 2021) |
≥ 18 years | Germany | |
| Molecular clamp stabilized spike protein (University of Queensland /GSK/Dynavax) |
Phase 1 ACTRN1262000067 4932P (120) |
Recruiting (-) |
18−55 years |
Australia | |
| RBD-based (Kentucky Bioprocessing, Inc) |
Phase 1/2 NCT04473690 (180) |
Not yet recruiting (November 2021) |
18−70 years |
USA | |
| S1-RBD-protein (COVAXX) | Phase 1 NCT04545749 (60) |
Recruiting (August 2021) |
20−55 years |
Taiwan | |
| S-2 P protein + CpG101 8(Medigen Vaccine Biologics corporation/NIAID /Dynavax |
Phase 1 NCT04487210 (45) |
Not yet recruiting (December 2021) |
20−50 years |
Taiwan | |
| RBD + Adjuvant (Instituto Finaly de Vacunas, Cuba |
Phase 1/2 IFV/COR/04 (676) |
Recruiting (Febuary 2021) |
19−80 years |
Cuba | |
| Peptide (FBRI SRC VB B VECTOR, Rospotrebnadzor , Koltsovo) |
Phase 1/2 NCT04527575 (100) |
Active, not recruit Ing (October 2020) |
18−60 Years |
Russia | |
| VLP | Plant-derived VLP (Medicago Inc. ./Universite’ Lava) |
Phase 1 NCT04450004 (180) |
Recruiting (April 2021) |
18−55 years |
Canada |
| RBD-HBsAg VLPs (SpyBiotech/serum Institute of India |
Phase 1/2 ACTRN126200000 817943 (280) |
Recruiting (-) |
18−79 years |
Australia | |
| Replicating viral vector | Intranasal flu-based- RBD (Beijing Wantai Biological Pharmacy/ Xiamen University |
Phase 1 ChiCTR2000037782 (60) |
Not yet recruiting (October 2021) |
≥ 18 years | China |
| Meascles-vector based (Institute Pasteur/Thermis/University of Pittsburg CVR/Merck Sharp & Dohme) |
Phase 1 NCT04497298 (90) |
Recruiting (October 2021) |
18−55 years |
France Belgium |